Greg Lazar received his BS in Molecular & Cell Biology and Chemistry from Penn State, his PhD in Molecular & Cell Biology from the University of California at Berkeley, and did postdoctoral research at the University of Cambridge, UK. Previously he led research groups at Eli Lilly and Xencor. Currently he is Senior Director and Principal Scientist in Antibody Engineering at Genentech. Dr. Lazar is an expert in biotherapeutic engineering and drug discovery, and has developed technologies and molecules that have led to 3 approved drugs and over 10 candidates across all stages of clinical trials. He has authored 40 scientific publications and is an inventor of over 30 patents. His current research focus is the development of novel antibody technologies to enable next generation therapeutics to treat unmet medical needs in oncology and neuroscience.